

Synthesis, Reactions, and Anti-arrhythmic activity of Substituted Heterocyclic Systems Using 5-Chloroanisic Acid as Starting Material

Ahmed F. A. Shalaby¹, Mohamed M. Abdulla^{2,*}, Abd El Galil E. Amr³, and Azza A. Hussain¹

¹ Chemistry Department, Faculty of Science, Cairo University, Cairo, Egypt

² Research Units, Hi-Care Pharmaceutical Co., Cairo, Egypt

³ National Research Center, Applied Organic Chemistry Department, Dokki, Cairo, Egypt

Received April 2, 2007; accepted (revised) April 20, 2007; published online July 13, 2007

© Springer-Verlag 2007

Summary. A series of substituted heterocyclic systems were prepared from *N*1-[4-(4-fluorocinnamoyl)phenyl]-5-chloro-2-methoxybenzamide, which was prepared from the corresponding 5-chloroanisic acid (2-methoxy-4-chlorobenzoic acid) as starting material. Treating of the cinnamoyl derivative with hydrazine hydrate in dioxane afforded a pyrazoline, which was reacted with morpholine and paraformaldehyde to give the *N*-substituted pyrazoline. Acylation of pyrazoline with acetyl chloride in dioxane afforded the *N*-acetyl analogue. Also, the cinamoyl derivative was reacted with methylhydrazine, phenylhydrazine, or ethyl cyanoacetate to yield the corresponding *N*-methyl-, *N*-phenylpyrazoline, pyrane, and pyridone derivatives. Condensation of the cinnamoyl derivative with cyanothioacetamide gave the pyridinethione derivative, which was treated with ethyl chloroacetate affording the ethyl carboxylate derivative. Also, it was reacted with malononitrile or ethyl acetoacetate to give the cyano amino analogues and ethyl carboxylate, which was reacted with methylhydrazine to give the (indazolyl)phenyl derivative. On the other hand, reaction of cinnamoyl derivative with acetyl acetone afforded the cyclohexenyl derivative, which was reacted with hydrazine hydrate to give the [methylindazolyl]phenyl derivative. Condensation of the cinnamoyl derivative with guanidine hydrochloride or thiourea afforded the aminopyrimidine derivative and thioxopyrimidine. The latter was condensed with chloroacetic acid to yield a thiazolopyrimidine, which was condensed with 2-thiophenealdehyde to yield the arylmethylene derivative, however, it was also pre-

pared directly from thiopyrimidine by the action of chloroacetic acid, 2-thiophenealdehyde, and anhydrous sodium acetate. The pharmacological screening showed that many of these compounds have good anti-arrhythmic activity and low toxicity.

Keywords. 5-Chloroanisic acid; 4-Fluorobenzaldehyde; Thioxopyrimidine; Thiazolopyrimidine; Anti-arrhythmic activity.


Introduction

In previous work we have reported on the substituted heterocyclic derivatives as analgesic, anti-convulsant, and antiandrogenic agents [1–4] and demonstrated their antimicrobial activity [5–8]. On the other hand, cyanopyridone and cyanopyridine derivatives are promising antimicrobial agents [9, 10] and display anticancer activities [11–15]. Some of the chiral heterocyclic compounds containing a pyridine moiety have been reported as anticancer and anti-inflammatory agents [16, 17]. In addition, the heterocyclic nitrogen derivatives exhibited a general ionophoric potency for divalent cations [18] and are used as novel thiocyanate-selective membrane sensors [19]. Recently, we reported that certain substituted heterocyclic compounds exhibited antiparkinsonian, anti-inflammatory, antimicrobial, and anticonvulsant activities [20–24]. In

* Corresponding author. E-mail: Mohamed_mostafa211@hotmail.com

view of these observations and in continuation of our previous work in heterocyclic chemistry, we synthesized some new heterocyclic compounds con-

taining pyridone, pyridinethione, pyrazoline, and pyrimidine rings and tested their anti-arrhythmic activities.




Scheme 1

Results and Discussion

Synthesis

The starting material **3** was synthesized from 5-chloroanisic acid (**1**) and *p*-aminoacetophenone accord-


ing to the mixed anhydride technique [16] providing **2**, followed by treating with 4-fluorobenzaldehyde in ethanolic piperidine to afford *N*1-[4-(4-fluorocinnamoyl)phenyl]-5-chloro-2-methoxybenzamide **3**. Cyclocondensation of **3** with hydrazine hydrate in



Scheme 2

refluxing dioxane afforded the pyrazoline **4**, which was treated with morpholine in the presence of para-formaldehyde to give the *N*-morpholinomethylpyr-

azoline **5**. But **4** was reacted with acetyl chloride in dioxane to yield the 1-acetylpyrazoline **6**, which was also prepared directly from **3** by the action of



Scheme 3

hydrazine hydrate in the presence of an acetic acid/acetic anhydride mixture. Also, **3** was treated with methylhydrazine or phenylhydrazine to yield *N*-methylpyrazoline **7** and *N*-phenylpyrazoline **8**. Condensation of **3** with ethyl cyanoacetate in the presence of sodium ethoxide in ethanol gave cyanopyrane **9**, but in the presence of ammonium acetate in *n*-butanol afforded cyanopyridone **10**, which was prepared also from **3** with cyanoacetamide under the same conditions (Scheme 1).

Condensation of **3** with cyanothioacetamide in the presence of ammonium acetate in *n*-butanol yielded pyridinethione **11**, which was treated with ethyl chloroacetate in the presence of *EtONa* to give ethyl-3-aminothieno[2,3-*b*]pyridine-2-carboxylate derivative **12**. But, **3** was condensed with malononitrile in refluxing *n*-butanol in the presence of ammonium acetate, which gave the cyanoaminopyridine **13**. In addition, **3** was reacted with ethyl acetoacetate in the presence of *EtONa* to yield ethyl 3-cyclohexene-1-carboxylate **14**, which was then reacted with methylhydrazine in refluxing ethanol to afford the *N*-methylpyrazolone **15** (Scheme 2).

On the other hand, reaction of **3** with acetylacetone in the presence of *EtONa* afforded 4-acetyl-3-oxo-1-cyclohexene **16**, which was treated with hydrazine hydrate in ethanol to give the 3-methylpyrazoline derivative **17**. Condensation of **3** with diamino reagents, namely, guanidine hydrochloride or thiourea in methanolic *MeONa* afforded the corresponding aminopyrimidine **18** and thioxopyrimidine **19**. Also, **19** was condensed with chloroacetic acid in a mixture of acetic acid/acetic anhydride in the presence of anhydrous sodium acetate to yield the corresponding thiazolopyrimidine **20**, which was condensed with 2-thiophenealdehyde in the presence of anhydrous sodium acetate and a glacial acetic acid/acetic anhydride mixture to yield arylmethylene derivative **21**. However, the latter compound was also prepared directly from **19** by the action of chloroacetic acid, 2-thiophenealdehyde, and anhydrous sodium acetate in the presence of acetic acid/acetic anhydride mixture (Scheme 3).

Pharmacological Screening

Procaine amide, 5 mg/kg iv, and lidocaine, 5 mg/kg iv, led to an increase in LD_{100} by 65%, which corresponds to a LD_{100} of approximately 9 μ g/100 mg.

Table 1. Anti-arrhythmic activities of the newly synthesized compounds

Compound in (5 mg/kg)	Percentage increase in $LD_{100}/\%$
3	76 ± 0.081
4	77 ± 0.092
5	no effect
6	48 ± 0.046
7	65 ± 0.063
8	67 ± 0.066
9	72 ± 0.072
10	54 ± 0.050
11	no effect
12	77 ± 0.077
13	no effect
14	79 ± 0.071
15	no effect
16	47 ± 0.041
17	37 ± 0.051
18	75 ± 0.081
19	86 ± 0.091
20	45 ± 0.051
21	78 ± 0.099

All data were significantly different from the normal control value at $P \leq 0.05$

From Table 1, compounds **5**, **11**, **13**, and **15** showed no anti-arrhythmic activities but compounds **7** and **8** displayed nearly equal anti-arrhythmic activities as procaine amide and lidocaine. Compounds **3**, **4**, **9**, **10**, **12**, **14**, **19**, **21**, and **18** are more active than procaine amide and lidocaine, they arranged in descending manner. Also, **6**, **10**, **16**, **20**, and **17** showed anti-arrhythmic activities less than procaine and lidocaine, they arranged in descending manner.

Structural Activity Relationship (SAR)

- The benzylidene moiety and a high degree of aromaticity is essential for anti-arrhythmic activity.
- Hetero-aromaticity increases the anti-arrhythmic activity.
- Fused ring systems give anti-arrhythmic activity but to a lower extent.

Determination of Acute Toxicity (LD_{50})

The LD_{50} was determined by using rats. They were injected with different increasing doses of the synthesized compounds. The dose that killed 50% of the animals was calculated according to Austen and Brocklehurst [25].

Table 2. Acute toxicity (LD_{50}) of the synthesized compounds

Compound no.	$LD_{50}/\text{mg kg}^{-1}$
3	242.52 ± 0.27
4	297.76 ± 0.25
5	294.33 ± 0.15
6	298.85 ± 0.19
7	238.87 ± 0.17
8	298.67 ± 0.22
9	317.99 ± 0.11
10	387.49 ± 0.19
11	309.29 ± 0.18
12	309.99 ± 0.22
13	374.33 ± 0.27
14	274.37 ± 0.29
15	285.89 ± 0.23
16	242.29 ± 0.29
17	338.44 ± 0.18
18	226.62 ± 0.19
19	278.22 ± 0.27
20	276.01 ± 0.19
21	298.22 ± 0.12

All data were significantly different from the normal control value at $P \leq 0.05$

Experimental

All melting points were taken on Electrothermal IA 9000 series digital melting point apparatus. Elemental analytical data (in accord with the calculated values) were obtained from the microanalytical unit, Cairo University, Cairo, Egypt. The IR spectra (KBr) were recorded on a Shimadzu CVT-04 spectrophotometer. The 1H NMR spectra were recorded at 270 MHz on a Varian EM-360 spectrometer using TMS as an internal standard. The mass spectra were performed using a Varian MAT CH-5 spectrometer (70 eV). All reactions were followed by TLC (silica gel, aluminum sheets 60 F₂₅₄, Merck).

N1-[4-(4-Fluorocinnamoyl)phenyl]-5-chloro-2-methoxybenzamide (3, C₂₃H₁₇FCINO₃)

A mixture of 0.303 g acetyl derivative **2** (1 mmol), 0.124 g 4-fluorobenzaldehyde (1 mmol) in 20 cm³ absolute ethanol and 0.5 cm³ piperidine was refluxed for 30 min. The reaction mixture was left overnight at room temperature, the obtained solid was filtered off and crystallized to give 0.35 g **3** (87%). Mp 268–269°C (*EtOH*); IR (film): $\bar{\nu}$ = 3340–3240 (NH), 1698, 1679 (2CO) cm⁻¹; 1H NMR (CDCl₃): δ = 3.57 (s, OCH₃), 6.91 (d, CH-arylidene), 7.23–7.78 (m, Ar-H + CH-arylidene), 10.66 (s, NH, exchangeable with D₂O) ppm; ^{13}C NMR (CDCl₃): δ = 57.10 (OCH₃), 164.98, 188.96 (2C=O), 129.10, 155.20 (C=C), 133.79, 127.90, 134.60, 128.70, 115.22, 159.50, 139.90, 117.40, 129.10, 142.70, 136.70, 130.0, 124.18, 148.90 (Ar-C) ppm; MS (EI, 70 eV): m/z (%) = 410 [M^+ , 12] and at 268 (100, base peak).

N1-[4-[5-(4-Fluorophenyl)-4,5-dihydro-1H-3-pyrazolyl]phenyl]-5-chloro-2-methoxybenzamide (4, C₂₃H₁₉FCIN₃O₂)

A solution of 0.41 g **3** (1 mmol) and 0.4 cm³ hydrazine hydrate (8 mmol) in 20 cm³ dioxane was refluxed for 2 h. The solvent was evaporated under reduced pressure, the residue was washed with *n*-hexane and crystallized to give 0.3 g **4** (71%). Mp 201–202°C (*MeOH*); IR (film): $\bar{\nu}$ = 3435–3285 (NH), 1698 (CO) cm⁻¹; 1H NMR (CDCl₃): δ = 2.15–2.24 (d, CH₂-pyrazoline), 3.52 (s, OCH₃), 3.86 (m, CH-pyrazoline), 6.95 (s, NH, exchangeable with D₂O), 7.28–7.94 (m, Ar-H), 10.55 (s, NH, exchangeable with D₂O) ppm; ^{13}C NMR (CDCl₃): δ = 56.19 (OCH₃), 165.10 (CONH₂), 45.71, 62.65, 156.10 (pyrazoline-C), 115.70, 118.60, 123.0, 128.40, 128.90, 129.30, 131.30, 133.81, 133.90, 139.40, 141.50, 147.90, 148.01, 161.65 (Ar-C) ppm; MS (EI, 70 eV): m/z (%) = 424 [M^+ , 16] and at 328 (100, base peak).

N1-[4-[N-Morpholinomethyl]-5-(4-fluorophenyl)-4,5-dihydro-1H-3-pyrazolyl]phenyl]-5-chloro-2-methoxybenzamide (5, C₂₈H₂₈FCIN₄O₃)

A mixture of 0.424 g **4** (1 mmol), ~0.1 g morpholine (1 mmol), and 0.2 g paraformaldehyde in 30 cm³ absolute ethanol was refluxed for 2 h. The reaction mixture was evaporated under reduced pressure, dried, and crystallized to give 0.29 g **5** (56%). Mp 118–120°C (*MeOH*); IR (film): $\bar{\nu}$ = 3386–3156 (NH), 1692 (CO) cm⁻¹; 1H NMR (CDCl₃): δ = 2.05–2.20 (d, CH₂-pyrazoline), 2.40–2.45 (m, CH₂-morpholine), 3.31–3.35 (m, CH₂-morpholine), 3.56 (s, OCH₃), 3.81 (s, N-CH₂-N), 3.88 (m, CH-pyrazoline), 7.43–8.17 (m, Ar-H), 10.66 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): m/z (%) = 523 [M^+ , 22] and at 119 (100, base peak).

N1-[4-[1-Acetyl-5-(4-fluorophenyl)-4,5-dihydro-1H-3-pyrazolyl]phenyl]-5-chloro-2-methoxybenzamide (6, C₂₅H₂₁FCIN₃O₃)

Method A: A mixture of 0.424 g **4** (1 mmol) and ~0.1 g acetyl chloride (1 mmol) in 30 cm³ dioxane was stirred at room temperature for 5 h. The reaction mixture was evaporated under reduced pressure, the product was extracted with dichloromethane, washed with aqueous sodium bicarbonate, dried over anhydrous MgSO₄, evaporated under reduced pressure, and crystallized to give 0.37 g **6** (80%). Mp 266–268°C (*MeOH*); IR (film): $\bar{\nu}$ = 3320–3100 (NH), 1718, 1694 (2CO) cm⁻¹; 1H NMR (CDCl₃): δ = 1.85 (s, CH₃), 2.10–2.18 (m, CH₂-pyrazoline), 3.53 (s, OCH₃), 3.85 (m, CH-pyrazoline), 7.26–7.98 (m, Ar-H), 10.46 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): m/z (%) = 466 [M^+ , 8] and at 280 (100, base peak).

Method B: A mixture of 0.41 g **3** (1 mmol) and 0.4 cm³ hydrazine hydrate (8 mmol) in 40 cm³ AcOH/Ac₂O (3/1) was refluxed for 3 h, allowed to cool, and then poured onto water. The obtained solid was filtered off and crystallized to give 0.34 g **6** (72%).

N1-[4-[1-Substituted-5-(4-fluorophenyl)-4,5-dihydro-1H-3-pyrazolyl]phenyl]-5-chloro-2-methoxybenzamide 7 and 8

General procedure: A solution of 0.41 g **3** (1 mmol) and methylhydrazine or phenylhydrazine (1.5 mmol) in 15 cm³

absolute ethanol was refluxed for 5 h. The reaction mixture was poured onto ice, the obtained solid was collect by filtration, dried, and crystallized to give 0.25 g **7** (58%) and 0.31 g **8** (62%).

*N*1-{4-[1-Methyl-5-(4-fluorophenyl)-4,5-dihydro-1*H*-3-pyrazolyl]phenyl}-5-chloro-2-methoxybenzamide (**7**, C₂₄H₂₁FCIN₃O₂)

Mp 273–275°C (MeOH); IR (film): $\bar{\nu}$ = 3360–3105 (NH), 1699 (CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 2.10–2.25 (d, CH₂-pyrazoline), 2.57 (s, N-CH₃), 3.54 (s, OCH₃), 3.87 (m, CH-pyrazoline), 7.13–7.96 (m, Ar-H), 10.60 (s, NH, exchangeable with D₂O) ppm; ¹³C NMR (CDCl₃): δ = 36.60 (N-CH₃), 55.20 (OCH₃), 164.91 (CONH), 43.20, 67.69, 155.10 (pyrazoline-C), 115.24, 117.10, 118.90, 120.14, 127.90, 128.40, 128.80, 129.59, 131.09, 133.70, 135.10, 139.10, 139.70, 158.10 (Ar-C) ppm; MS (EI, 70 eV): m/z (%) = 438 [M⁺, 16] and at 186 (100, base peak).

*N*1-{4-[1-Phenyl-5-(4-fluorophenyl)-4,5-dihydro-1*H*-3-pyrazolyl]phenyl}-5-chloro-2-methoxybenzamide (**8**, C₂₉H₂₃FCIN₃O₂)

Mp 218°C (MeOH); IR (film): $\bar{\nu}$ = 3350–3145 (NH), 1692 (CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 1.99–2.16 (d, CH₂-pyrazoline), 3.56 (s, OCH₃), 3.91 (m, CH-pyrazoline), 7.10–7.98 (m, Ar-H), 10.58 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): m/z (%) = 500 [M⁺, 100, base peak].

*N*1-{4-[3-Cyano-2-oxo-6-(4-fluorophenyl)-2*H*-4-pyranyl]phenyl}-5-chloro-2-methoxybenzamide (**9**, C₂₆H₁₆ClFN₂O₄)
A solution of 0.41 g **3** (1 mmol), 0.13 cm³ ethyl cyanoacetate (1.2 mmol), and 68 mg of sodium ethoxide (1 mmol) in 20 cm³ absolute ethanol was refluxed for 2 h. The reaction mixture was evaporated under reduced pressure, the residue was solidified with *n*-hexane, the obtained solid was filtered off, and crystallized to give 0.32 g **9** (67%). Mp 267–269°C (MeOH/toluene); IR (film): $\bar{\nu}$ = 3405–2900 (NH), 2226 (CN), 1715, 1698 (2CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 3.53 (s, OCH₃), 7.01 (s, pyrane-H), 7.12–7.96 (m, Ar-H), 10.58 (s, NH, exchangeable with D₂O) ppm; ¹³C-NMR (CDCl₃): δ = 56.38 (OCH₃), 117.88 (CN), 163.78 (CONH), 106.08, 131.08, 145.10, 154.70, 157.78 (pyrane-C), 114.73, 116.50, 117.88, 128.15, 129.47, 129.84, 130.25, 133.90, 134.09, 139.90, 144.91, 144.98, 153.17, 166.60 (Ar-C) ppm; MS (EI, 70 eV): m/z (%) = 475 [M⁺, 32] and at 351 (100, base peak).

*N*1-{4-[3-Cyano-2-oxo-6-(4-fluorophenyl)-1,2-dihydro-4-pyridinyl]phenyl}-5-chloro-2-methoxybenzamide (**10**, C₂₆H₁₇FCIN₃O₃)

Method A: A solution of 0.41 g **3** (1 mmol), 0.13 cm³ ethyl cyanoacetate (1.2 mmol), and 0.616 g ammonium acetate (8 mmol) in 20 cm³ *n*-butanol was refluxed for 2 h. The formed precipitate after cooling was filtered off, dried, and crystallized to give 0.32 g **10** (68%). Mp 258–260°C (EtOH); IR (film): $\bar{\nu}$ = 3452–2685 (NH), 2218 (CN), 1696, 1678 (2CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 3.55 (s, OCH₃), 7.22–8.12 (m, Ar-

H + CH-pyridine), 8.72 (s, NH exchangeable with D₂O), 10.55 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): m/z (%) = 474 [M⁺, 22] and at 238 (100, base peak).

Method B: A solution of 0.41 g **3** (1 mmol), 0.1 g cyanoacetamide (1.2 mmol), and 0.616 g ammonium acetate (8 mmol) in 20 cm³ *n*-butanol was refluxed for 2 h. After cooling, the solid formed was filtered off, dried, and crystallized to give 0.34 g **10** (72%).

*N*1-{4-[3-Cyano-2-thioxo-6-(4-fluorophenyl)-1,2-dihydro-4-pyridinyl]phenyl}-5-chloro-2-methoxybenzamide (**11**, C₂₆H₁₇ClFN₃O₂S)

A solution of 0.41 g **3** (1 mmol), 0.12 g cyanothioacetamide (1.2 mmol), and 0.616 g ammonium acetate (8 mmol) in 25 cm³ *n*-butanol was refluxed for 3 h. After cooling the precipitated was filtered off, dried, and crystallized to give 0.45 g **11** (92%). Mp 148–150°C (toluene); IR (film): $\bar{\nu}$ = 3460–3250 (NH), 2219 (CN), 1697 (CO), 1230 (CS) cm⁻¹; ¹H NMR (CDCl₃): δ = 3.59 (s, OCH₃), 4.56 (s, CSNH, exchangeable with D₂O), 7.15–8.11 (m, Ar-H + CH-pyridinethione), 10.64 (s, NH, exchangeable with D₂O) ppm; ¹³C NMR (CDCl₃): δ = 56.19 (OCH₃), 117.80 (CN), 164.92 (CONH), 112.86, 138.90, 145.36, 163.75, 171.50 (pyridine-C), 112.82, 112.90, 118.10, 126.80, 127.77, 129.70, 129.87, 134.09, 134.18, 140.90, 141.20, 145.36, 153.10, 163.75 (Ar-C) ppm; MS (EI, 70 eV): m/z (%) = 490 [M⁺, 65] and at 229 (100, base peak).

*Ethyl 3-amino-4-{4-[(5-chloro-2-methoxybenzoyl)amino]phenyl}-6-(4-fluorophenyl)thieno[2,3-*b*]pyridine-2-carboxylate* (**12**, C₃₀H₂₃FCIN₃O₄S)

A solution of 0.5 g **11** (1 mmol), 0.122 g ethyl chloroacetate (1 mmol), and 0.68 g sodium ethoxide (10 mmol) in 10 cm³ ethanol was refluxed for 4 h. The reaction mixture was evaporated under reduced pressure, the obtained solid was filtered off, dried, and crystallized to give 0.4 g **12** (70%). Mp 301–303°C (MeOH/methylacetate); IR (film): $\bar{\nu}$ = 3490–3265 (NH, NH₂), 1735, 1693 (2CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 1.10 (t, CH₃), 3.62 (s, OCH₃), 4.51 (q, OCH₂), 5.75 (s, NH₂, exchangeable with D₂O), 7.12–7.97 (m, Ar-H + CH-pyridine), 10.66 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): m/z (%) = 576 [M⁺, 15] and at 530 (100, base peak).

*N*1-{4-[6-Amino-5-cyano-2-(4-fluorophenyl)-4-pyridyl]phenyl}-5-chloro-2-methoxybenzamide (**13**, C₂₆H₁₈ClN₄O₂)

A solution of 0.41 g **3** (1 mmol), ~0.1 g malononitril (1.2 mmol), and 0.616 g ammonium acetate (8 mmol) in 25 cm³ *n*-butanol was refluxed for 3 h. After cooling, the precipitate was filtered off, dried, and crystallized to give 0.34 g **13** (72%). Mp 228–230°C (acetone/MeOH); IR (film): $\bar{\nu}$ = 3460–3250 (NH, NH₂), 2223 (CN), 1694 (CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 3.51 (s, OCH₃), 5.45 (s, NH₂, exchangeable with D₂O), 6.96–7.97 (m, Ar-H + CH-pyridine), 10.64 (s, NH, exchangeable with D₂O) ppm; ¹³C NMR (CDCl₃): δ = 56.19 (OCH₃), 116.10 (CN), 164.75 (CONH), 111.50, 137.43, 145.10, 163.80, 176.11 (pyridine-C), 111.68, 113.10, 117.90, 125.60, 127.55, 129.10, 130.25, 134.10, 134.17, 141.10, 141.80, 143.20, 154.74, 163.88 (Ar-C) ppm; MS (EI, 70 eV): m/z (%) = 473 [M⁺, 100, base peak].

Ethyl 4-[4-[(5-chloro-2-methoxybenzoyl)amino]phenyl]-2-oxo-6(S)-(4-fluorophenyl)-3-cyclohexene-1(S)-carboxylate (**14**, C₂₉H₂₅FCINO₅)

A solution of 0.41 g **3** (1 mmol), 0.15 cm³ ethyl acetoacetate (1.2 mmol), and ~0.1 g sodium ethoxide (1.5 mmol) in 25 cm³ absolute ethanol was refluxed for 3 h. The reaction mixture was evaporated under reduced pressure, the residue was crystallized to give 0.48 g **14** (92%). Mp 164–166°C (*EtOH*); IR (film): $\bar{\nu}$ = 33100–2980 (NH), 1728, 1718, 1697 (3CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 1.05 (t, CH₃), 2.49 (m, CH₂-cyclohexene), 3.52 (s, OCH₃), 3.78 (d, CH-cyclohexene), 3.88 (m, CH-cyclohexene), 4.18 (m, OCH₂), 6.57 (s, CH-ene), 7.10–7.96 (m, *Ar*-H), 10.72 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): m/z (%) = 522 [M⁺, 7] and at 279 (100, base peak).

N1-[4-(3-Oxo-4-(4-fluorophenyl)-3,3a(S),4(S),5-tetrahydro-2-methyl-2H-6-indazolyl)phenyl]-5-chloro-2-methoxybenzamide (**15**, C₂₈H₂₃FCIN₃O₃)

A solution of 0.522 g **14** (1 mmol) and 0.46 g methylhydrazine (1 mmol) in 10 cm³ absolute ethanol was refluxed for 1.5 h. The reaction mixture was left overnight at room temperature, the obtained solid was filtered off and crystallized to give 0.24 g **15** (48%). Mp 154–156°C (*EtOH*); IR (film): $\bar{\nu}$ = 3375–3205 (NH), 1715, 1694 (2CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 2.54 (s, CH₃), 2.70 (m, CH₂-indazolyl), 3.14 (d, CH-indazolyl), 3.52 (d, CH-indazolyl), 3.62 (s, OCH₃), 6.78 (s, CH-indazolyl), 7.21–8.05 (m, *Ar*-H), 10.48 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): m/z (%) = 504 [M⁺, 100, base peak].

N1-{4(R)-[4-Acetyl-3-oxo-5(R)-(4-fluorophenyl)-1-cyclohexenyl]phenyl}-5-chloro-2-methoxybenzamide (**16**, C₂₈H₂₃FCINO₄)

A solution of 0.41 g **3** (1 mmol), 0.12 cm³ acetyl acetone (1.2 mmol) and ~0.1 mg sodium ethoxide (1.5 mmol) in 10 cm³ absolute ethanol was refluxed for 2 h. The reaction mixture was evaporated under reduced pressure, the residue was crystallized to give 0.46 g **16** (94%). Mp 213–215°C (acetone/*MeOH*); IR (film): $\bar{\nu}$ = 3380–3190 (NH), 1728, 1710, 1699 (3CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 1.84 (s, COCH₃), 2.67 (m, CH₂-cyclohexene), 3.54 (s, OCH₃), 3.76 (m, CH-cyclohexene), 3.83 (m, CH-cyclohexene), 6.84 (s, CH-cyclohexene), 7.12–7.89 (m, *Ar*-H), 10.66 (s, NH, exchangeable with D₂O) ppm; ¹³C NMR (CDCl₃): δ = 29.70 (CH₃), 56.91 (OCH₃), 163.40 (CONH), 36.46, 40.49, 68.10, 132.25, 159.68, 198.31 (cyclohexenone-C), 207.11 (CO), 113.20, 117.33, 117.80, 124.89, 126.91, 129.0, 130.28, 134.80, 135.60, 142.60, 142.70, 151.60, 154.70, 164.11 (*Ar*-C) ppm; MS (EI, 70 eV): m/z (%) = 492 [M⁺, 20] and at 381 (100, base peak).

N1-[4-[3-Methyl-4-(4-fluorophenyl)-4,5-dihydro-3a(R)H-6-indazolyl]phenyl]-5-chloro-2-methoxybenzamide (**17**, C₂₈H₂₃FCIN₃O₂)

A solution of 0.5 g **16** (1 mmol) and 0.4 cm³ hydrazine hydrate (8 mmol) in 5 cm³ absolute ethanol was refluxed

for 3 h. The separated solid was filtered off and crystallized to give 0.42 g **17** (87%). Mp 163–165°C (*EtOH*); IR (film): $\bar{\nu}$ = 3340–3180 (NH), 1697 (CO, amide) cm⁻¹; ¹H NMR (CDCl₃): δ = 1.98 (s, CH₃), 3.28 (m, CH₂-indazolyl), 3.58 (s, OCH₃), 3.79 (m, CH-indazolyl), 4.09 (m, CH-indazolyl), 6.78 (s, CH-indazolyl), 7.12–7.89 (m, *Ar*-H), 10.65 (s, NH, exchangeable with D₂O) ppm; ¹³C NMR (CDCl₃): δ = 17.40 (CH₃), 56.17 (OCH₃), 163.16 (CONH), 36.61, 39.31, 51.11, 134.18, 143.60, 144.80, 154.10 (indazolyl-C), 113.18, 117.56, 118.17, 126.70, 129.35, 130.18, 130.38, 134.18, 138.16, 142.16, 143.21, 154.57, 154.81, 164.28 (*Ar*-C) ppm; MS (EI, 70 eV): m/z (%) = 488 [M⁺, 14] and at 251 (100, base peak).

Substituted Pyrimidine Derivatives **18** and **19**

A solution of 0.41 g **3** (1 mmol), diamino reagents, namely, guanidine hydrochloride or thiourea (1.2 mmol) and ~0.1 g sodium methoxide (1.5 mmol) in 25 cm³ absolute methanol was refluxed for 2–4 h. The reaction mixture was evaporated to dryness under reduced pressure, dried and crystallized to give 0.41 g **18** (91%) and 0.30 g **19** (65%).

N1-[4-[2-Amino-6-(4-fluorophenyl)-4-pyrimidinyl]phenyl]-5-chloro-2-methoxybenzamide (**18**, C₂₄H₂₀FCIN₄O₂)

Mp 210–212°C (*AcOMe*); IR (film): $\bar{\nu}$ = 3450–3200 (NH, NH₂), 1696 (CO) cm⁻¹; ¹H NMR (CDCl₃): δ = 3.53 (s, OCH₃), 5.18 (d, Ha-pyrimidine), 5.46 (s, NH₂, exchangeable with D₂O), 6.98–8.04 (m, *Ar*-H + Hb-pyrimidine), 8.40 (s, NH, exchangeable with D₂O), 10.42 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): m/z = 451 [M⁺, 12] and at 200 (100, base peak).

N1-[4-[6-(4-Fluorophenyl)-2-thioxo-4-pyrimidinyl]phenyl]-5-chloro-2-methoxybenzamide (**19**, C₂₄H₁₉FCIN₄O₂S)

Mp 230–232°C (*AcOMe*); IR (film): $\bar{\nu}$ = 3460–3210 (NH), 1697 (CO), 1225 (CS) cm⁻¹; ¹H NMR (CDCl₃): δ = 3.58 (s, OCH₃), 5.22 (d, Ha-pyrimidine), 7.24–8.31 (m, *Ar*-H + Hb-pyrimidine), 8.42 and 8.54 (2s, 2NH, exchangeable with D₂O), 10.65 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): m/z (%) = 468 [M⁺, 100, base peak].

7-[4-[4-(5-Chloro-2-methoxybenzoyl)amino]phenyl]-3-oxo-5-(4-fluorophenyl)-2,3-dihydro-5H-thiazolo[3,2-a]-pyrimidine (**20**, C₂₆H₁₉FCIN₃O₃S)

A mixture of 0.468 g **19** (1 mmol) and 0.1 g chloroacetic acid (1 mmol) was dissolved in 40 cm³ *AcOH*/*Ac*₂O (1/3) in the presence of 1.5 g anhydrous sodium acetate and was refluxed for 6 h. The reaction mixture was cooled and poured onto cold water with stirring, the formed solid was filtered off and crystallized to give 0.35 g (68%) **20**. Mp 188–190°C (*AcOH*/*H*₂O); IR (film): $\bar{\nu}$ = 3355–3295 (NH), 1735, 1698 (2CO) cm⁻¹; ¹H NMR (*DMSO*-d₆): δ = 3.53 (s, OCH₃), 3.72 (s, CH₂-thiazole), 5.52 (d, Ha, pyrimidine), 7.26–7.50 (m, *Ar*-H + Hb-pyrimidine), 10.25

(s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): *m/z* (%) = 508 [M⁺, 10] and at 228 (base peak, 100).

7-{4-[4-(5-Chloro-2-methoxybenzoyl)amino]phenyl}-2-(2-thienylmethylene)-3-oxo-5-(4-fluorophenyl)-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine (**21**, C₃₁H₂₁FCIN₃O₃S₂)

Method A: A mixture of 0.468 g **19** (1 mmol), 0.1 g chloroacetic acid (1 mmol), and 1.5 g anhydrous sodium acetate in 40 cm³ AcOH/Ac₂O (1/3) and 0.112 g 2-thiophenealdehyde (1 mmol) was refluxed for 6 h. The reaction mixture was cooled and poured onto ice-water, the obtained solid was collected by filtration, and crystallized to give 0.5 g (84%) **21**. Mp 212–214°C (AcOH/H₂O); IR (film): $\bar{\nu}$ = 3355–3325 (NH), 1716, 1694 (2CO) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 3.58 (s, OCH₃), 5.56 (d, Ha, pyrimidine), 7.32–7.65 (m, Ar-H + Hb-pyrimidine + benzylic proton + thiophen-H), 10.15 (s, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): *m/z* (%) = 602 [M⁺, 100, base peak].

Method B: A mixture of 0.5 g **20** (1 mmol) and 0.112 g 2-thiophenealdehyde (1 mmol) in 40 cm³ AcOH/Ac₂O (1/3) was refluxed for 5 h, allowed to cool, then poured onto water, the solid formed was collected by filtration, and crystallized to yield 0.42 g (72%) **21**, as identified by its mp, mixed mp, and *R_f* value on TLC by comparison with authentic sample from method A.

Pharmacological Assay

Anti-arrhythmic Activity [26–31]

Purpose and Rational

The plant alkaloid aconitine persistently activates sodium channel. Infusion of aconitine in the anesthetized rat causes ventricular arrhythmias. Drugs considered to have anti-arrhythmic properties can be tested in aconitine-intoxicated rats.

Procedure

Male Ivanovas rats weighing 300–350 g are used. The animals are anesthetized by intra peritoneal injection of 1.25 g/kg urethane: 5 mg/kg aconitine dissolved in 0.1 N HNO₃ is administered by continuous infusion into the saphenous vein of 0.1 cm³/min and the ECG in lead II is recorded every 30 sec. The test compound is injected IV at a screening dose of 3 mg/kg 5 min before the start of the aconitine infusion, 24 animals are used per compound.

Evaluation

The anti-arrhythmic effect of a test compound is measured by the amount of aconitine/100 g animal.

(Duration of infusion) which induces.

- Ventricular extra systoles.
- Ventricular tachycardia.
- Ventricular fibrillation.

Higher doses of aconitine in the treated group as compared to an untreated control group are an indication of anti-arrhythmic activity.

Statistical significance between the groups is assessed by the Student's *T*-test.

References

- [1] Amr AE, Hegab MI, Ibrahim AA, Abdulla MM (2003) *Monatsh Chem* **134**: 1395
- [2] Amr AE, Abdel-Latif NA, Abdalla MM (2006) *Bioorg Med Chem* **14**: 273
- [3] Amr AE, Sayed HH, Abdulla MM (2005) *Arch Pharm Chem Life Sci* **338**: 433
- [4] Amr AE (2005) *Z Naturforsch* **60b**: 90
- [5] Amr AE, Abdel-Latif NA, Abdalla MM (2006) *Acta Pharm* **56**: 203
- [6] Attia A, Abdel-Salam OI, Amr AE (1997) *Egypt J Chem* **40**: 317
- [7] Attia A, Abdel-Salam OI, Stibor I, Amr AE, Budesinsky M (2000) *Egypt J Chem* **43**: 187
- [8] Attia A, Abdel-Salam OI, Amr AE (2000) *Egypt J Chem* **43**: 297
- [9] Amr AE (2000) *Ind J Heterocycl Chem* **10**: 49
- [10] Amr AE, Mohamed AM, Ibrahim AA (2003) *Z Naturforsch* **58b**: 861
- [11] Hammam AG, Fahmy AFM, Amr AE, Mohamed AM (2003) *Ind J Chem* **42B**: 1985
- [12] Hammam AG, Abdel Hafez NA, Midura WH, Mikolajczyk M (2000) *Z Naturforsch* **55b**: 417
- [13] Hammam AG, Sharaf M, Abdel-Hafez NA (2001) *Ind J Chem* **40B**: 213
- [14] Hammam AG, Magdy AZ, Fatma AE, Khalid MHH (1996) *Egypt J Pharm Sci* **37**: 565
- [15] Hammam AG, Zaki MEA, El-Assasy ME (1997) *Egypt J Pharm Sci* **38**: 292
- [16] Abo-Ghalia M, Amr AE (2004) *Amino Acids* **26**: 283
- [17] Abo-Ghalia M, Amr AE, Abdulla MM (2003) *Z Naturforsch* **58b**: 903
- [18] Hassan SSM, Abou-Ghalia MH, Amr AE, Mohamed AHK (2003) *Talanta* **60**: 81
- [19] Hassan SSM, Abou-Ghalia MH, Amr AE, Mohamed AHK (2003) *Anal Chem Acta* **482**: 9
- [20] Amr AE, Abdalla MM (2006) *Bioorg Med Chem* **14**: 4341
- [21] Amr AE, Abdalla MM (2006) *Arch Pharm Chem Life Sci* **339**: 88
- [22] Amr AE, Nermien MS, Mohamed MA (2007) *Monatsh Chem* Accepted in 10-1-2007
- [23] Amr AE (2006) *Z Naturforsch* **61b**: 1335
- [24] Amr AE, Ashraf MM, Salwa FM, Nagla AA, Hammam AG (2006) *Bioorg Med Chem* **14**: 5481
- [25] Austen KF, Brocklehurst WE (1961) *J Exp Med* **113**: 521
- [26] Walker MJA, Curtius MJ, Hearse DJ, Campbell RWF, Jams MJ, Yellon DM, Coker SM, Harness JB, Harron DWG, Miggins AJ, Julian DG, Lab MJ, Manning AS, Northover BJ, Parratt JR, Riemersma RA, Riva E, Russell DC, Sheridan DJ, Winslow E, Woodward B (1988) *Cardiovasc Res* **22**: 447
- [27] Vaille A, Scotto di Tella AM, Maldonado J, Vanelle P (1992) *Meth Find Exp Clin Pharmacol* **14**: 183
- [28] Bazzani C, Genedani S, Tugliavini S, Bertolini A (1989) *J Pharm Pharmacol* **41**: 651
- [29] DeClerk FLUHR (1993) *J Cardiovasc Pharmacol* **22**: 120
- [30] Winslow E (1980) *Br J Pharmac* **71**: 615
- [31] Winslow E (1981) *J Cardiovasc Pharmac* **3**: 87